Treatment timing in glioblastoma showed inconsistent links with outcomes
A small review found conflicting survival signals for chemotherapy and radiotherapy timing, alongside a possible safety tradeoff for morning chemotherapy.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Some studies linked morning temozolomide or afternoon radiotherapy with longer survival, but results were inconsistent. A pooled chemotherapy analysis found no survival or progression-free survival difference and reported more bone-marrow suppression with morning dosing. The review treats these findings as ideas to test, rather than evidence strong enough to guide a change in treatment timing.
The studies differed enough to prevent a pooled summary estimate, and some evidence was observational. Follow-up and detailed timing comparisons are missing from the abstract, limiting assessment of the reported survival differences.
What timing meant here
The review examined whether the hour of treatment was associated with survival, disease progression, or surgical outcomes. Chemotherapy, radiotherapy, and surgery were considered separately, so a signal for one treatment cannot be assumed to apply to another.
Signals did not consistently repeat
Morning chemotherapy looked favorable in a retrospective cohort, but that pattern did not hold in a larger pooled analysis. Radiotherapy findings also varied, and the reviewed surgical evidence did not show a meaningful timing effect.
The original publication
Impact of chronotherapy and time-of-day on surgical and adjuvant outcomes in glioblastoma and mixed high-grade glioma patients: a systematic review.
Shah S, Punukollu A, Lucke-Wold B
Neurochirurgie · 2026
- PubMed ID
- 41651408
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.